Insulin resistance and management of the menopause: A clinical hypothesis in practice

Menopause International

Volumn 17, Issue 1, 2011, Pages 24-28

  Whitcroft, Sovra ^a   Herriot, Anne ^a  

^a The Surrey Park Clinic: Health and Hormone Clinic   (United Kingdom)

Author keywords

hormones; HRT; insulin resistance; menopause; metabolic syndrome; vasomotor symptoms

Indexed keywords

ADIPONECTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ETHINYLESTRADIOL; METFORMIN; NEUROLEPTIC AGENT; PROGESTERONE;

ABDOMINAL OBESITY; BREAST CANCER; DIABETES MELLITUS; DIETARY INTAKE; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; HYPOTHESIS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; LIFESTYLE MODIFICATION; MENOPAUSAL SYNDROME; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK ASSESSMENT;

AGED; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; INSULIN RESISTANCE; MENOPAUSE; MIDDLE AGED; OBESITY; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 79953172567     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2011.011003     Document Type: Review

References (47)

1. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabetes Med 2002; 19: 527–34
2. Bloomgarden ZT. The 1st World Congress on the Insulin Resistance Syndrome. Diabetes Care 2004; 27: 602–609
3. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391–406
4. Alberti KGMM, Eckel RH, Grundy SM,, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–5
5. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynaecol Endocrinol 1997; 11: 341–55
6. Solomon CG, Seely EW. Brief review: hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension 2001; 37: 232–239
7. Carrington B, Sacks G, Regan L. Recurrent miscarriage: pathophysiology and outcome. Curr Opin Obstet Gynecol 2005; 17: 591–597
8. Baptiste CG, Battista M, Trottier A, Baillargeon J. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2010; 122: 42–52
9. NHS Information Centre. Health Survey for England 2009: Trend tables. London: NHS Information Centre, 2010
10. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356–359
11. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004; 53: 495–499
12. Godsland IF, Crook D, Simpson R,, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–81
13. Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 1993; 23: 466–73
14. Foooooo CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr 1992; 55: 950–954
15. McClenaghan NH. Determining the relationship between dietary carbohydrate intake and insulin resistance. Nutr Res Rev 2005; 18: 222–40
16. Salway J. Medical Biochemistry at a Glance. Oxford: Blackwell, 2006
17. Bolognesi C. Prediction of glucose and insulin responses of normal subjects after consuming mixed meals varying in energy, protein, fat, carbohydrate and glycemic index. J Nutr 1996; 126: 2807–12
18. Connor H, Annan F, Bunn E,, et al. The implementation of nutritional advice for people with diabetes. Diabet Med 2003; 20: 786–807
19. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome – the optimal diet. Br J Nutr 2000; 83(Supplement 1):S143–S148
20. Volek JS, Feinman RD. Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction. Nutr Metab (Lond) 2005; 2: 31
21. Kitabchi AE, Temprosa M, Knowler WC,, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404–14
22. Cameron A. The metabolic syndrome: validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction. Maturitas 2010; 65: 117–21
23. Bloomgarden ZT. The 6th Annual World Congress on the Insulin Resistance Syndrome. Diabetes Care 2009; 32: e114–e121
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65
25. Schulman IH, Zhou M. Vascular insulin resistance: a potential link between cardiovascular and metabolic diseases. Curr Hypertens Rep 2009; 11: 48–55
26. Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc Nutr Soc 2007; 66: 82–95
27. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. See www.dietandcancerreport.org (last accessed 4 March 2011)
28. Pollak MN. Insulin-like growth factors and neoplasia. Cancer (review) 2004; 4: 505–17
29. Kaaks R. Serum C-peptide, insulin-like growth factor (IGF)-I,IGF-binding proteins and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592–600
30. Renehan AG,, et al. Insulin-like growth factor (IGF)-I,IGF binding protein-3 and cancer risk:systematic review and meta-regression analysis. Lancet 2004; 363: 1346–53
31. Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer taret:blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2002; 2: 191–207
32. Bloomgarden ZT. Third Annual World Congress on the Insulin Resistance Syndrome: associated conditions. Diabetes Care 2006; 29: 2165–74
33. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579–91
34. Pichard C, Plu-Bureau G, Neves E, Castro M, Gompel A. Insulin resistance, obesity and breast cancer risk. Maturitas 2008; 60: 19–30
35. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006; 94: 1221–5
36. Soliman PT, Wu D, Tortolero-Luna G,, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006; 106: 2376–81
37. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33: 1304–08
38. Decensi A, Puntoni M, Goodwin P,, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451–61
39. Pines A, Sturdee DW, Birkhäuser MH, Schneider HPG, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181–94
40. Stevenson JC. HRT and cardiovascular disease. In: Lumsden MA (ed). Best Practice and Research Clinical Obstetrics and Gynaecology, vol 23. London: Elsevier, 2009: 109–20
41. Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8: 538–54
42. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535–82
43. Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 2002; 102: 151–66
44. Godsland IF. Oestrogens and insulin secretion. Diabetologia 2005; 48: 2213–20
45. Herriot AM, Whitcroft S, Jeanes Y. A retrospective audit of patients with polycystic ovary syndrome: the effects of a reduced glycaemic load diet. J Hum Nutr Diet 2008; 21: 337–45
46. Herriot AM, Whitcroft S, Jeanes Y. A low glycaemic load diet reduces risk factors for the metabolic syndrome and type 2 diabetes in lean and overweight menopausal women and women with polycystic ovary syndrome. J Hum Nutr Diet 2009; 22: 595
47. Hawley JA, Lessard SJ. Exercise training-induced improvements in insulin action. Acta Physiol (Oxf) 2008; 192: 127–35